Active	Status	Sponsor type	Region	Phase	Filter
10 Active 1 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

10 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wang, Guixia
PB119, NCT04504370: Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects	Completed	3	273	RoW	GLP-1 receptor agonist, Placebo, PB-119 Placebo	PegBio Co., Ltd.	Type 2 Diabetes Mellitus (T2DM)	03/22	11/22
RECAM, NCT04807348: Chiglitazar Added to Metformin for Type 2 Diabetes	Completed	3	533	RoW	Chiglitazar 32mg, Bilessglu, CS038, Chiglitazar 48mg, Placebo, Chiglitazar simulator, Metformin Hydrochloride, Glucophage	Chipscreen Biosciences, Ltd.	Type 2 Diabetes	02/23	02/23
SURMOUNT-OSA, NCT05412004: Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea	Completed	3	469	Europe, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Sleep Apnea, Obesity	03/24	03/24
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time	Completed	3	928	Europe, Canada, Japan, US, RoW	Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec	Eli Lilly and Company	Diabetes, Type 2 Diabetes	04/24	04/24
ATTAIN-OSA, NCT06649045: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight	Recruiting	3	600	Europe, Japan, US, RoW	Orforglipron, LY3502970, Placebo	Eli Lilly and Company	OSA, Overweight or Obesity	11/26	01/27
TRIUMPH-4, NCT05931367: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee	Active, not recruiting	3	405	Europe, Canada, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Obesity, Overweight, Osteo Arthritis Knee	02/26	03/26
TRIUMPH-1, NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight	Active, not recruiting	3	2300	Europe, Canada, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea	04/26	05/26
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight	Active, not recruiting	3	1000	Europe, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea	05/26	05/26
NCT06778850: A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants	Recruiting	1/2	131	RoW	MDR-001, palcebo	MindRank AI Ltd	Overweight and Obese Volunteers	07/25	12/25
NCT06606509: The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM).	Not yet recruiting	N/A	1000	RoW	Continuous Glucose Monitoring System (GX-01S)	Nanjing First Hospital, Nanjing Medical University	Type1 Diabetes Mellitus	10/26	06/27